RecruitingNCT06410300

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

A Multi-Center Pilot Biomarker Study With Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Sponsor

Bo Lu

Enrollment

125 participants

Start Date

Apr 19, 2024

Study Type

OBSERVATIONAL

Conditions

Lung Cancer

Summary

The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

Patient older than 18 years age
Diagnosis of locally advanced lung cancer (NSCLC or SCLC) with planned curative radiotherapy (45Gy and above) and planned consolidation immunotherapy.
Patients who are not receiving concurrent chemotherapy and radiotherapy are eligible.
Patients on a clinical trial that includes thoracic radiotherapy and immunotherapy are eligible and may be co-enrolled to this study.
ECOG performance status of 0-2
Life expectancy of 6 months or longer
Patient able to provide a written informed consent prior to study entry

Exclusion Criteria3

Prior thoracic radiotherapy to chest.
Patients are excluded if they are not candidates for curative thoracic radiotherapy or immunotherapy.
Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study.